Non-Cystic Fibrosis Bronchiectasis Market

• In 2022, the market size of Non-cystic Fibrosis Bronchiectasis was the largest in China among the 7MM + China, accounting for approximately USD 3,495 million, which is further expected to increase by 2032.
• The diagnosed prevalence of Non-cystic Fibrosis Bronchiectasis has been increasing due to a better detection rate with advanced imaging techniques and improved awareness.
• The current treatment of NCFB manages symptoms, reduces exacerbations, prevents disease progression, and requires frequent hospitalization, the intensity of which varies across settings.
• One of the major concerns in understanding the market for Non-cystic Fibrosis Bronchiectasis is that there is a paucity of evidence to validate many of the interventions used in the daily management of NCFB. No consensus guidelines are available globally or in the US and Japan.
• Emerging therapies include Insmed/AstraZeneca’s Brensocatib, Zambon’s colistimethate sodium, CSL Behring’s CSL787, Chiesi Farmaceutici’s CHF 6333, Boehringer Ingelheim’s BI 1291583, have the potential to create a positive shift in the Non-cystic Fibrosis Bronchiectasis market size.
• Though NCFB is currently treated with antibiotics, none is approved for inhalation to treat pseudomonal infection in NCFB. If approved, Zambon’s colistimethate sodium would be the first FDA-approved treatment indicated for patients with NCFB chronically colonized with P. aeruginosa.
• With expected Phase III results by 2024, brensocatib can potentially address the unmet need for NCFB and become a blockbuster drug in the NCFB market with a thirst for approved products.

DelveInsight’s “Non-cystic Fibrosis Bronchiectasis Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Non-cystic Fibrosis Bronchiectasis, historical and forecasted epidemiology as well as the Non-cystic Fibrosis Bronchiectasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.

Non-cystic Fibrosis Bronchiectasis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM + China Non-cystic Fibrosis Bronchiectasis market size from 2019 to 2032. The report also covers current Non-cystic Fibrosis Bronchiectasis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Non-cystic Fibrosis Bronchiectasis Treatment Market

Non-cystic Fibrosis Bronchiectasis Overview

Non-cystic Fibrosis Bronchiectasis is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree, leading to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are cough, sputum production, and frequent respiratory infections.

It is associated with comorbidities, such as anxiety, depression, and fatigue, significantly impacting the quality of life. Patients with NCFB require longer hospital stays and more outpatient visits. Symptoms can include shortness of breath, wheezing, coughing blood, and chest pain. Patients often have recurrent chest infections. The severity of symptoms can vary widely. Some people have a few symptoms that do not often appear, while others have wide-ranging daily symptoms. The symptoms worsen if the patient develops an exacerbation (usually caused by a chest infection).

The etiology of NCFB is multifactorial, with many NCFB cases associated with idiopathic, post-infective, COPD, asthma, and other etiologies. As bronchiectasis is a multidimensional and etiologically diverse disease, no single parameter can be used to determine its overall severity and prognosis. In this regard, two different validated scores are currently used to assess the severity of NCFB: the Bronchiectasis Severity Index (BSI) and the FACED (F: forced expiratory volume in 1 s [FEV1]; A: age; C: chronic colonization by Pseudomonas aeruginosa [PA], E: radiological extension [number of pulmonary lobes affected], and D: dyspnea score).

Non-cystic Fibrosis Bronchiectasis Diagnosis

Bronchiectasis is diagnosed via a chest computed tomography (CT) scan. A chest X-ray, bronchoscopy, lung function, blood tests, sputum culture, and other tests (e.g., immune function, sweat test, and genetics) for associated diseases may also be performed.

Before a diagnosis of bronchiectasis is made, symptoms are often attributed to asthma or a viral infection. If a chronic wet cough fails to respond to 4 weeks of appropriate antibiotics, it increases the probability of underlying bronchiectasis and is an indication for referral to a specialty respiratory service.

Further details related to country-based variations are provided in the reported…

Non-cystic Fibrosis Bronchiectasis Treatment

The treatment of bronchiectasis focuses on managing symptoms, slowing the decline in lung function, and preventing exacerbations. Chest physiotherapy is a well-established treatment with little in the way of side effects. Some patients may respond to more specialist treatments, such as regular antibiotics, often in a low-dose macrolide three times a week.

The current treatment regime includes antibiotics, corticosteroids, bronchodilators, medication for acid suppression, active mucous agents, and measures to enhance bronchial hygiene. Significant numbers of neutrophils within the airway lumen suggest a role for anti-inflammatory therapy in this disease. Two commonly used classes of anti-inflammatories are corticosteroids and macrolides.

Non-pharmacological mucus clearance (or airway clearance techniques (ACTs)) within the margins of cystic fibrosis bronchiectasis or NCFB patients represents a vital component of treatment, permitting a noninvasive, low-risk strategy to decrease acute complications. Some commonly used ACTs include postural drainage, manual techniques involving some form of percussion or rhythmic vibration, active cycle of breathing technique, positive expiratory pressure, etc.

However, it is a universal truth that no single treatment approach is appropriate for all Non-cystic Fibrosis Bronchiectasis patients. Current remedies are labor-consuming and have side effects due to the restricted number of alternatives available. They have limits that lead to increased resistance to existing treatments, necessitating new drug development.

Non-cystic Fibrosis Bronchiectasis Epidemiology

As the market is derived using a patient-based model, the Non-cystic Fibrosis Bronchiectasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis, Gender-specific cases of Non-cystic Fibrosis Bronchiectasis, Severity-specific cases of Non-cystic Fibrosis Bronchiectasis, Etiology-associated cases of Non-cystic Fibrosis Bronchiectasis, and Microbiology of Non-cystic Fibrosis Bronchiectasis patients in the 7MM + China covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China from 2019 to 2032. The total diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis in the 7MM + China comprised approximately 9,397,292 cases in 2022 and are projected to increase during the forecasted period.

• The total number of diagnosed prevalent cases of Non-cystic Fibrosis Bronchiectasis in the United States was around 368,286 cases in 2022.
• China contributed to the largest diagnosed prevalent population of Non-cystic Fibrosis Bronchiectasis, acquiring ~85.64% of the 7MM + China in 2022. Whereas the US, EU4 and the UK, and Japan accounted for around 3.92%, 5.24%, and 5.20% of the total population share, respectively, in 2022.
• In the US, females diagnosed with Non-cystic Fibrosis Bronchiectasis are higher in number than males. In 2022, cases of Non-cystic Fibrosis Bronchiectasis among females were approximately 242,332, while among the male population, there were approximately 125,954 NCFB cases. These numbers are expected to rise during the study period.
• According to DelveInsight estimates, in EU4 and the UK, the prevalence of moderate cases of Non-cystic Fibrosis Bronchiectasis is the highest, followed by mild Non-cystic Fibrosis Bronchiectasis and severe Non-cystic Fibrosis Bronchiectasis cases. In 2022, there were approximately 196,848 moderate, 152,557 mild, and 142,715 severe Non-cystic Fibrosis Bronchiectasis cases in EU4 and the UK, projected to increase during the forecast period.
• In 2022, 97,810, 4,891, 7,336, 6,113, 206,624, and 166,278 Non-cystic Fibrosis Bronchiectasis cases were associated with post-infection, COPD, immunodeficiency, asthma, others, and unknown/Idiopathic etiologies in Japan.
• In 2022, there were 2,172,915 NCFB cases colonized with P. aeruginosa in China, followed by 1,851,002 Non-cystic Fibrosis Bronchiectasis cases colonized with H. influenza, 1,770,524 Non-cystic Fibrosis Bronchiectasis cases with no pathogen growth, 1,609,567 NCFB cases colonized with other pathogens, and 643,827 Non-cystic Fibrosis Bronchiectasis cases colonized with S. pneumonia.

Discover key insights and trends in Non-Cystic Fibrosis Bronchiectasis (NCFB) epidemiology. Stay ahead with our comprehensive forecast for 2032.

Non-cystic Fibrosis Bronchiectasis Drug Chapters

The drug chapter segment of the Non-cystic Fibrosis Bronchiectasis report encloses a detailed analysis of Non-cystic Fibrosis Bronchiectasis marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps understand the Non-cystic Fibrosis Bronchiectasis clinical trial details, expressive pharmacological action, agreements, and collaborations, approval and patent details, each drug's advantages and disadvantages, and the latest news and press releases.

Non-cystic Fibrosis Bronchiectasis Emerging Drugs

Brensocatib: Insmed/AstraZeneca

Brensocatib, formerly known as INS1007, is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases. Insmed is conducting a Phase III ASPEN trial to confirm the results seen in the Phase II WILLOW trial and to support a new drug application (NDA) for brensocatib for treating adult patients with bronchiectasis. With enrollment completion anticipated in 1Q of 2023, the topline results are expected by 2Q of 2024. The drug is expected to be a promising agent, with its launch anticipated in 2025 in the United States market. Also, because of brensocatib’s unique profile, Key Opinion Leaders (KOLs) are buoyant that the drug could be a game changer in the bronchiectasis market. It is anticipated to be used in a greater number of patients as compared to the other late-stage emerging drug in development.

Discover cutting-edge developments in Non-Cystic Fibrosis Bronchiectasis (NCFB) treatments with our Pipeline Insight 2024 report. Stay informed now!

Drug Class Insights

The existing Non-cystic Fibrosis Bronchiectasis treatment is mainly dominated by classes such as antibiotics, corticosteroids, bronchodilators, acid suppressants, and active mucous agents. Besides pharmacological agents, non-pharmacologic measures are recommended to improve bronchial hygiene.

Antibiotics are the most prescribed medication across the US, followed by bronchodilators and steroids. It is expected that the antibiotics will continue to maintain dominance in the Non-cystic Fibrosis Bronchiectasis market. The antibiotic use associated with Non-cystic Fibrosis Bronchiectasis includes antibiotics for exacerbation, suppressive antibiotics, rotating oral suppressive antibiotics, or inhaled suppressive antibiotics. Inhaled antibiotics are generally considered effective and safer than oral and intravenous varieties; however, there are differences of opinion concerning the same that interventions reduce the number of exacerbations, sputum production, and bacterial load in the airways, they also cause more localized side effects that can result in their withdrawal. Further, comparative trials on inhaled antibiotics are limited and controversial due to the bias in population selection and methodological variability.

The inhaled antibiotic serves as an alternate, cheaper mode of delivery of life-saving medication without the emergence of systemic complications. Chronic and high-dose antibacterial drugs, especially macrolides and quinolones, are associated with ototoxicity and nephrotoxicity, which can lead to failure of completion. Three types of inhaled non-dry antibiotics used for Non-cystic Fibrosis Bronchiectasis patients include tobramycin, colistin, and amikacin.

Inhaled corticosteroids (ICS) have also been investigated in Non-cystic Fibrosis Bronchiectasis, and studies have been conducted to compare the use of high-dose ICS and medium-dose ICS. The use of macrolides for the treatment of Non-cystic Fibrosis Bronchiectasis has become a common approach in recent years due to several characteristics, like their anti-inflammatory effects, their ability to decrease mucus production, and their well-known effect on Gram-positive cocci and atypical pathogens.

However, the current treatment classes do not address the underlying causes and are solely treating the symptoms of the disease.

Non-cystic Fibrosis Bronchiectasis Market Outlook

Non-cystic Fibrosis Bronchiectasis is a condition that has received little attention and has made little progress. Current remedies are labor-consuming and have side effects due to the restricted number of alternatives available. Present therapies have limits; for example, neutrophilic inflammation, important to bronchiectasis pathogenesis, has proven to be mostly resistant to existing treatments. This necessitates the development of new drugs. The available antibiotic therapy is associated with the threat of antimicrobial resistance, thus requiring regimes that support antimicrobial stewardship. To ensure the effective administration of high quantities of medicine within the airways with lower systemic adverse effects, aerosolized and inhaled administration within the lung has piqued attention.

The current market has been segmented into different commonly used therapeutic classes based on the prevailing treatment pattern across the 7MM + China, which presents minor variations in the overall prescription pattern. Antibiotics, bronchodilators, and steroids are the major classes covered in the forecast model.

There are currently no approved therapies for NCFB, but in recent years, there has been increased interest in developing new therapies due to the increasing prevalence and perceived unmet needs. The current pipeline for Non-cystic Fibrosis Bronchiectasis is still not curative, with most therapies only improve the current treatment regime but do not create something novel. With very limited late-stage products, molecules with a novel mechanism of action and curative capacities are needed. Some, like reversible dipeptidyl peptidase 1 inhibitor, and ease administering of cell membrane modulators, are being developed, but the overall market growth will be limited with no blockbuster treatment. A few early-stage products are expected to improve the regime and be more effective than the current antibiotic therapy, but even they are developed as adjunctive preventive treatments and not curative or first-line therapies. Thus the pipeline for modest and is expected to experience only some shift in the existing market scenario during the forecast period (2023–2032).

Key players such as Insmed/ AstraZeneca (brensocatib), Zambon (colistimethate sodium), CSL Behring (CSL787), Chiesi Farmaceutici (CHF 6333), Boehringer Ingelheim (BI 1291583), and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Non-cystic Fibrosis Bronchiectasis.

• The total market size of Non-cystic Fibrosis Bronchiectasis in the 7MM + China is approximately USD 3,495 million in 2022 and is projected to increase during the forecast period (2023–2032).
• The market size in the 7MM + China will increase at a CAGR of 2.8% due to increasing awareness of the disease and the launch of the emerging therapy.
• In 2022, antibiotics were the most prescribed medication across the US, followed by bronchodilators and steroids. Though the revenue will decline, antibiotics will maintain dominance among the current therapy classes throughout the study period.
• Among EU4 and the UK countries, the UK accounts for the maximum market size in 2022, while France occupied the bottom of the ladder in 2022.
• Japan accounted for the third largest market among the 7MM + China with USD 440 million in 2022, expected to increase during the forecast period (2023–2032).
• In China, among the emerging therapies, Zambon’s colistimethate sodium, the first to enter, is expected to peak in its eighth year.

Non-cystic Fibrosis Bronchiectasis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019–2032. For example, Brensocatib (formerly INS1007), a reversible inhibitor of DPP1 for the treatment of Non-cystic Fibrosis Bronchiectasis, with an anticipated entry by 2025 in the US, is predicted to have a medium uptake during the forecast period.

Further detailed analysis of emerging therapies drug uptake in the report…

Non-cystic Fibrosis Bronchiectasis Pipeline Development Activities

The report provides insights into Non-cystic Fibrosis Bronchiectasis Clinical Trails within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Non-cystic Fibrosis Bronchiectasis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Non-cystic Fibrosis Bronchiectasis evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the University of Texas Health Science Center, San Antonio, Baltimore, Harvard Medical School, Boston, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Non-cystic Fibrosis Bronchiectasis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, administration frequency, administration route, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in Non-cystic Fibrosis Bronchiectasis trials, one of the most important primary outcome measures is the rate of decrease of pulmonary exacerbations (PEs).

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Non-cystic Fibrosis Bronchiectasis Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers’ concerns about budget impact. The high cost of rare disease drugs usually had a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Non-cystic Fibrosis Bronchiectasis Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of Non-cystic Fibrosis Bronchiectasis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
• A detailed review of the Non-cystic Fibrosis Bronchiectasis market, historic and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM + China drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM + China Non-cystic Fibrosis Bronchiectasis market.

Non-cystic Fibrosis Bronchiectasis Report Insights

• Non-cystic Fibrosis Bronchiectasis Patient Population
• Non-cystic Fibrosis Bronchiectasis Therapeutic Approaches
• Non-cystic Fibrosis Bronchiectasis Pipeline Analysis
• Non-cystic Fibrosis Bronchiectasis Market Size and Trends
• Existing and future Market Opportunity
• Upcoming Non-cystic Fibrosis Bronchiectasis Therapies

Non-cystic Fibrosis Bronchiectasis Report Key Strengths

• 10 Years Forecast
• The 7MM + China Coverage
• Non-cystic Fibrosis Bronchiectasis Epidemiology Segmentation
• Key Cross Competition
• Attribute Analysis
• Non-cystic Fibrosis Bronchiectasis Drugs Uptake
• Non-cystic Fibrosis Bronchiectasis Market Forecast Assumptions

Non-cystic Fibrosis Bronchiectasis Report Assessment

• Current Non-cystic Fibrosis Bronchiectasis Treatment Practices
• Non-cystic Fibrosis Bronchiectasis Unmet Needs
• Non-cystic Fibrosis Bronchiectasis Pipeline Product Profiles
• Non-cystic Fibrosis Bronchiectasis Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Non-cystic Fibrosis Bronchiectasis Market Drivers
• Non-cystic Fibrosis Bronchiectasis Market Barriers

Key Questions Answered In The Non-cystic Fibrosis Bronchiectasis Market Report

Non-cystic Fibrosis Bronchiectasis Market Insights 

• What was the total non-cystic fibrosis bronchiectasis market size, the market size by therapies, market share (%) distribution in 2019, and what would it look like in 2032? What are the contributing factors for this growth?
• How will DPP1 inhibitors as a class affect the treatment paradigm of Non-cystic Fibrosis Bronchiectasis?
• How will antibiotics compete with steroids and bronchodilators?
• Which class is going to be the largest contributor in 2032?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Non-cystic Fibrosis Bronchiectasis Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Non-cystic Fibrosis Bronchiectasis? What will be the growth opportunities across the 7MM + China with respect to the patient population pertaining to Non-cystic Fibrosis Bronchiectasis?
• What is the historical and forecasted Non-cystic Fibrosis Bronchiectasis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China?
• Why do only limited patients appear with symptoms? Why is the current year diagnosis rate not high?
• What factors are affecting the increase in the diagnosis of Non-cystic Fibrosis Bronchiectasis?

Current Non-cystic Fibrosis Bronchiectasis Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Non-cystic Fibrosis Bronchiectasis? What are the current guidelines for treating Non-cystic Fibrosis Bronchiectasis in the US and Europe?
• How many companies are developing therapies for the treatment of Non-cystic Fibrosis Bronchiectasis?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Non-cystic Fibrosis Bronchiectasis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What have key designations been granted for the emerging therapies for Non-cystic Fibrosis Bronchiectasis?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?
• What are the 7MM + China historical and forecasted market of Non-cystic Fibrosis Bronchiectasis?

Reasons to buy Non-cystic Fibrosis Bronchiectasis Market Report

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Non-cystic Fibrosis Bronchiectasis Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.